<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04104815</url>
  </required_header>
  <id_info>
    <org_study_id>DA26</org_study_id>
    <nct_id>NCT04104815</nct_id>
  </id_info>
  <brief_title>GI Tolerance and Acceptability of a New Thickener</brief_title>
  <official_title>A Study to Evaluate the GI Tolerance and Acceptability of a New Thickener for Dysphagia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is designed to evaluate the gastrointestinal tolerance and acceptability of&#xD;
      a new thickener for dysphagia patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study Timing&#xD;
  </why_stopped>
  <start_date type="Actual">February 5, 2021</start_date>
  <completion_date type="Actual">February 5, 2021</completion_date>
  <primary_completion_date type="Actual">February 5, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bristol Stool Scale</measure>
    <time_frame>Study Day 1 to Study Day 7</time_frame>
    <description>The Bristol Stool Scale is used to describe the consistency of stools. Numbers 1-7 are assigned to stools based on descriptions on the scale from hard to liquid.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HCP Product Satisfaction Questionnaire</measure>
    <time_frame>Study Day 7</time_frame>
    <description>5 Questions; 3 of the questions utilize a 5 point scale in the positive direction; 2 of the questions are closed categories yes or no.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Palatability of Study Product</measure>
    <time_frame>Study Day 1 and Study Day 7</time_frame>
    <description>A 5 point scale in the positive direction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Product Compliance</measure>
    <time_frame>Study Day 1 to Study Day 7</time_frame>
    <description>Patient thickened fluids consumption records</description>
  </primary_outcome>
  <other_outcome>
    <measure>Weight</measure>
    <time_frame>Study Day 1 and Study Day 7</time_frame>
    <description>Weight in Kg</description>
  </other_outcome>
  <other_outcome>
    <measure>Medications</measure>
    <time_frame>Study Day 1 to Study Day 7</time_frame>
    <description>Current medication use</description>
  </other_outcome>
  <other_outcome>
    <measure>Thickness of drinks prescribed</measure>
    <time_frame>Study Day 1 to Study Day 7</time_frame>
    <description>Current prescription per IDDSI guidelines</description>
  </other_outcome>
  <other_outcome>
    <measure>Medical aetiology of dysphagia</measure>
    <time_frame>Study Day 1 and Study Day 7</time_frame>
    <description>Current documentation of medical aetiology</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Gastro-intestinal Tolerance</condition>
  <arm_group>
    <arm_group_label>Experimental Thickener</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder thickener</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Experimental Thickener</intervention_name>
    <description>Use to thicken liquids</description>
    <arm_group_label>Experimental Thickener</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has voluntarily signed and dated an ICF approved by an IRB/IEC, and provided&#xD;
             applicable privacy authorization prior to any participation in the study.&#xD;
&#xD;
          -  Subject is diagnosed with dysphagia.&#xD;
&#xD;
          -  Subject is under the care of a Speech and Language Therapist and is currently using a&#xD;
             thickener.&#xD;
&#xD;
          -  Subject currently has normal GI function.&#xD;
&#xD;
          -  Subject is interested in participating in the study, willing to comply with the study&#xD;
             protocol and product.&#xD;
&#xD;
          -  Subject who is able to consent and is able to evaluate the product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a normal swallow.&#xD;
&#xD;
          -  Subject at high risk of aspiration with oral fluids requiring nil by mouth and enteral&#xD;
             tube feeding.&#xD;
&#xD;
          -  Subject has impaired renal function.&#xD;
&#xD;
          -  Subject has liver failure, decompensated chronic liver disease, active hepatitis B or&#xD;
             C receiving treatment, or hepatic encephalopathy.&#xD;
&#xD;
          -  Subject has severe dementia or unable to communicate or consent or delirium, eating&#xD;
             disorder, history of significant neurological or psychiatric disorder affecting&#xD;
             abilities to answer questions, alcoholism, substance abuse or other conditions that&#xD;
             may interfere with study product consumption or compliance with study protocol&#xD;
             procedures.&#xD;
&#xD;
          -  Participant is known to be allergic or intolerant to any ingredient found in the study&#xD;
             product.&#xD;
&#xD;
          -  Participation in another study that has not been approved as a concomitant study.&#xD;
&#xD;
          -  Subject has a clinical condition that is contraindicated with this product such as&#xD;
             hepatic and renal disease.&#xD;
&#xD;
          -  Subject has a clinical condition which may interfere with gastrointestinal tolerance.&#xD;
&#xD;
          -  Subject is pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Stevenson</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <removed_countries>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2019</study_first_posted>
  <last_update_submitted>March 14, 2021</last_update_submitted>
  <last_update_submitted_qc>March 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

